Teva Pharma (TEVA) Reports In-Line Q3 EPS, Offer FY Guidance

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $4 billion versus the consensus estimate of $4.07 billion.

GUIDANCE:

Teva Pharma sees FY2020 EPS of $2.40-$2.55, versus the consensus of $2.51. Teva Pharma sees FY2020 revenue of $16.5-16.8 billion, versus the consensus of $16.7 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity